

Antimicrobials, Multiple Drug Resistance & Antibiotics Resistance

4th International Conference on **Antibiotics R&D, B2B** April 20-21, 2018
Las Vegas, Nevada, USA

The preclinical development of a novel antimicrobial peptide with strong antibacterial and anti-inflammatory activity: Systemic and pulmonary delivery with nanoparticles

Alessandro Pini

University of Siena, Italy
SetLance srl, Italy

The peptide SET-M33 is currently under preclinical development for the setup of a new antibacterial agent against the most important Gram-negative pathogens (Brunetti et al. 2016, Sci Reports). It is a synthetic molecule produced in tetra branched form, that makes the peptide particularly stable for *in vivo* use. SET-M33 has a potent activity against a large panel of Gram-negative bacteria, with MIC₉₀ below 1.5 μM for multi resistant strains of *Pseudomonas aeruginosa* and *Klebsiella pneumoniae*. Its mechanism of action involves LPS binding and membrane permeation (van der Weide et al. 2017, Biochim Biophys Acta). In in-vivo models of *P. aeruginosa* infections the peptide enabled a survival percentage of 60-80% in sepsis and lung infections when injected I.V or by nebulization. The peptide is also able to neutralize LPS thus inhibiting the expression of inflammatory cytokines. This produces a strong anti-inflammatory effect as demonstrated in vivo in models of pulmonary infections (Brunetti et al. 2016, J Biol Chem). Plasma clearance, biodistribution, acute toxicity, synergistic activity with traditional drugs, and resistance selection profiles in comparison with molecules already used in the clinical practice, have been evaluated. The conjugation of SET-M33 to nanoparticles based on different carriers (dextran, poly-lactide-co-glycoside, and others) is under evaluation for the improved delivery and slow release of the molecule administered by aerosol or systemically. Preclinical tests including ADME, safety pharmacology and manufacturing processes are in the last stages of development, thus SET-M33 is expected to enter into clinical trials in the next 18 months.

Biography

Alessandro Pini is Associate Professor of Biochemistry at the University of Siena, Italy. He has a degree in Biology, a PhD in Biotechnology, and a Postgraduate degree in Clinical Biochemistry. He was a Visiting Researcher at the Centre of Protein Engineering, MRC, Cambridge, UK, and at the Swiss Federal Institute for Research (ETH), Zurich, Switzerland. He is the Founder and President of the company SetLance, based in Siena. He is author of dozens of publications and inventor in 12 patents regarding antibodies and peptides and their applications.

pinia@unisi.it

Notes: